Research Center Profile:
Michigan Head-Pain & Neurological Institute
The Michigan
Head-Pain & Neurological Institute (MHNI), the nation’s
first comprehensive head pain treatment and research center, was
founded by Dr. Joel Saper in 1978 to provide intensive, balanced
treatment of headache and other painful disorders. The Institute is
the only center of its kind to be accredited by both the Joint
Commission on Accreditation of Healthcare Organizations (JCAHO,
www.JCAHO.com)
and the Commission on Accreditation of Rehabilitation Facilities
(CARF, www.CARF.org). On-site neurodiagnostic and
laboratory services are available to MHNI patients. Testing is
performed by highly qualified licensed technicians and interpreted
by physician specialists at the Institute. The Laboratory Division
is fully accredited by the Commission on Office Laboratory
Accreditation (COLA, www.COLA.org) and has been repeatedly
recognized for its commitment to excellence in laboratory
testing.
For close to three decades the Institute has been focused on
addressing the needs of patients with headache and other painful
illnesses, and neurological disorders through advanced clinical
care, research, and health education.
Please refer to our main web site at
www.MHNI.com for
a full description of the services provided at MHNI. Selected
information is available on this web site and can be accessed by
clicking the hyperlink above. You may also
contact
us by email with any questions or for an appointment with our
research staff.
MHNI has been involved in over 200 research and clinical trials
since its inception in 1978.
The Research
Division of MHNI has studied acute and preventive treatment of
Migraine Headache in pediatric, adolescent, and adult populations;
Tension Headache; Cluster Headache; Neuropathic Pain Syndromes;
Fibromyalgia; Insomnia and other Sleep Disorders; and Smoking
Cessation
The Institute has conducted clinical trials with pharmaceutical
industry sponsors that include Abbott, Allergan., AstraZeneca ,
Bristol-Myers Squibb, Capnia, Cephalon, Cypress, Carnick, CoCensys,
Eisai, Elan, Endo, Forest, GlaxoSmithKline, Janssen, R.W. Johnson,
Eli Lilly, Merck, NBI, NPS, Novartis, Ortho-McNeil, Parke-Davis,
Pfizer, Pozen, Purdue Pharma, RPR, Sandoz, Schwarz,Searle, Takeda,
TorreyPines, ucb Pharma,Vernalis, Winston, and others.
Michigan HeadPain & Neurological Institute is located in Ann
Arbor, surrounded by the University of Michigan, Eastern Michigan
University, and Washtenaw Community College. We include the local
academic community as well as the greater Detroit metropolitan area
in our research patient population. The Institute is located 23
miles from the Detroit Metro Airport, and has spacious free
parking.
The
MHNI campus includes 20 clinical examination rooms, acute care
accommodations, procedure rooms for infusion and interventional
treatment, physical therapy, laboratory, behavioral medicine, and
neurodiagnostic facilities and staff. The Institute maintains
strict confidentiality and security standards compliant with CARF
and JCAHO requirements. The multidisciplinary team of professionals
at MHNI includes specialists in Neurology, Internal Medicine,
Anesthesiology, and Psychology / Neuropsychology (PhDs), as well as
Physical Therapists, Physician Assistants, Registered Nurses,
Medical Technologists (ASCP), and Psychometrician.
MHNI Clinical Research Division provides:
- Physician Investigators and Sub-Investigators on-site Monday
through Friday
- Experienced full-time RN Study Coordinators
- Contract and Budget Facilitator
- Regulatory Specialist
- Extensive Subject Database with Cross-Reference Capability
- Prompt / Accurate Data Entry
- Computerized Scheduling and Patient Tracking
- Customized Source Documents
- HIPAA Compliance
- Dedicated Monitor Office
- Utilization of Central IRBs
Joel R. Saper, M.D., F.A.C.P.,
F.A.A.N.
Founder and Director of the Institute and the inpatient Head Pain
Treatment Unit at Chelsea Community Hospital. Dr. Saper has been a
Principal Investigator in over 100 studies and has over 25 years of
experience in original research and sponsored clinical trials.
Board certified in both Neurology and Pain Medicine, Dr.Saper’s
work is widely published in peer reviewed journals and professional
literature.
Charles David Gordon, MD, formerly at the John R. Graham
Headache Center in Boston, has been with MHNI since 1990. He has
served as Principal Investigator in clinical trials for Acute
Migraine in adolescents and Migraine Prophylaxis in adults, as well
as Sub-Investigator and Cardiac Consultant for many additional
studies.
Alvin E. Lake III, PhD, is Senior Research Psychologist and
Director of the Behavioral Medicine Division at MHNI. He has
extensive training and experience in protocol development,
statistical analysis, and data reporting, all utilized in Institute
clinical and program outcome studies. Dr. Lake has achieved both
national and international recognition for his clinical work and
research publications.
James R. Weintraub, DO, a board-certified Neurologist and Sleep
Disorders Specialist, came to MHNI in 1995. He is Principal
Investigator in studies of Diabetic Neuropathy, Post-Herpetic
Neuralgia, and other painful neuropathic conditions, and Insomnia
and other Sleep Disorders. Dr. Weintraub is also an active
Sub-Investigator in chronic and acute headache treatment
trials.
Alicia R. Prestegaard, MD, is board certified in both Neurology
and Pain Medicine. She also completed a fellowship in
electromyography. Dr. Prestegaard’s focus in clinical trials, as
well as clinical practice, is the treatment of Recurrent Headache
and other Chronic Pain Conditions.
Shamas Moheyuddin, MD, completed his residency in Anesthesiology
and a Fellowship in Interventional Pain Management before coming to
MHNI in 2005. In addition to his clinical practice of invasive and
non-invasive treatment options for a wide range of painful
disorders, he is currently involved in studies evaluating
Peripheral Nerve Stimulation for the treatment of Chronic
Migraine.
For more information on our investigators please click
here.
Marjorie Winters, R.N., Division Director,
Research & Education, has over 15 years of experience in
directing MHNI staff original clinical studies and coordinating
industry sponsored pharmaceutical trials. She facilitates budget
and contract processes, and serves as clinical / administrative
liaison.
Shawn Szalay, RN, CCRP, had experience in
Clinical Drug Safety Monitoring before coming to MHNI in 2002 to
become Manager of Pharmaceutical Trials. She oversees staff
training, and has developed a successful subject recruitment
program resulting in meeting or exceeding enrollment goals well
within target timelines.
Michelle Riggs, RN, came to MHNI in
1999. She has served as primary Coordinator in studies for Adult
and Adolescent Migraine, Fibromyalgia, and other long- and
short-term trials.
Amy Amazeen joined the staff at MHNI in 2001.
Her specialty is ‘Study Start-Up’ , Regulatory Documents, and data
entry in a variety of RDC programs.
Jennifer Majestic, RN, on staff at MHNI since
2002, has been primary Study Coordinator for clinical trials in
Acute and Chronic Migraine, Health Economics, Post-Herpetic
Neuralgia, and others.
For more information on our staff please click
here.
The Research Division of MHNI draws from a population of
pediatric, adolescent, adult, and geriatric patients primarily in
the southeastern region of Michigan, northwest Ohio, and northeast
Indiana; a population base of over 6 million. The clinic provides
over 20,000 visits per year to headache and pain patients
nationwide; depending on the parameters of the study, research
participants may be drawn from this population as well.
Marjorie Winters, R.N
Division Director, Research & Education
Michigan Head-Pain & Neurological Institute
3120 Professional Drive
Ann Arbor, MI 48104-5199
USA
Phone: 734-677-6000, x 140
Fax: 734-677-0227
EMail: MWinters@mhni.com
Web Site: http://www.mhni.com/
The following trial(s) are actively recruiting patients:
If you are interested in contacting this center to discuss placing a clinical
trial there, please complete and send the E-mail form below. A representative from
the research center will then follow up with you.
